Who we are

BiVictriX is a rapidly emerging biotechnology company applying a novel approach to develop safer, more effective cancer therapies.

We have developed Bi-Cygni® therapeutics, which are uniquely selective for particular cancer types, to enable higher dosing and more aggressive cancer eradication without causing harmful side effects.

We apply state of the art techniques to identify combinations of cancer-specific targets for both solid and liquid tumours.

Our novel approach to cancer therapy

Selectivity

By selectively identifying cancer cells, we can avoid hitting vital healthy cells with anti-cancer treatments.

High potency

This enables a much higher dose of treatment to be safely given to the patient to effectively kill the cancer cells.

More effective

Enabling more effective anti-cancer treatment without causing harmful side-effects.

Bi-Cygni® therapeutics make this possible

BiVictriX team

Executive team

Tiffany Thorn
Chief Executive Officer
View Profile
Dr Oliver Schon
VP, Product Development & CMC
View Profile
Glyn Baker
Chief Financial Officer
View Profile
Dr Kevin Moulder
Chief Scientific Officer
View Profile

Board of Directors

Tiffany Thorn
Chief Executive Officer
View Profile
Iain Ross
Non-Executive Chairman
View Profile
Prof. Robert Hawkins
Non-Executive Director
View Profile
Dr Michael Kauffman
Non-Executive Director
View Profile
Susan Lowther
Non-Executive Director
View Profile
Drummond Paris
Senior Independent Non-Executive Director
View Profile

Join us

We seek to recruit the best talent and are open to collaborate with academic and industry leaders in order to progress our pipeline. Technology and translational expertise are equally important to our vision of moving cancer therapies into the clinic fast. As a focussed SME Biotech, we pride ourselves in defining success criteria upfront, valuing individual contributions as well as team efforts and our perseverance to find solutions to clinical challenges. If our vision, fast pace, and drive to succeed aligns with your ambition, please get in touch.

View careers